Ventyx – Talk Bio

Actionable Insights Powered by AI

Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease

9 months ago talkbio0Tagged Biosciences, Crohn 's disease, Drug Development, Failure (biologic function), Inhibitor, Phase 2 Clinical Trials, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure

Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback

9 months ago talkbio0Tagged Arthritis, Psoriatic, Biosciences, Crohn 's disease, Drug Development, Inflammatory disorder, Inhibitor, Phase 2 Failure, Psoriasis, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.